Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib in Recurrent Osteosarcoma Localized to the Lung
NCT00752206Phase 2Terminated
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Start
- Mar 2009
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteosarcoma (OS) comparing Saracatinib with Placebo (2 arms). Primary endpoint: Progression Free Survival Rate at 5 years. Started Mar 2009; status: terminated.
02
Drugs
saracatinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT00752206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00752206.